Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro

Anticancer Research

Volumn 30, Issue 1, 2010, Pages 87-96

  Zhang, Ning ^a,b   Sanders, Andrew J ^a   Ye, Lin ^a   Kynaston, Howard G ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Motility and adhesion; Urothelial cancer of bladder; Vascular endothelial growth inhibitor (VEGI)

Indexed keywords

MESSENGER RNA; VASCULOTROPIN INHIBITOR;

ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STROMA CELL;

CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 77649269121     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Epstein JI, Amin MB, Reuter VR and Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435-1448, 1998.
3. Oyasu R: World Health Organization and International Society of Urological Pathology classification and two-number grading system of bladder tumors. Cancer 88: 1509-1512, 2000.
4. Crew JP: Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer. Eur Urol 35: 2-8, 1999.
5. Crew JP, O'Brien T, Bicknell R, Fuggle S, Cranston D and Harris AL: Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 161: 799-804, 1999.
6. Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G and Truneh A: Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204: 35-46, 1997.
7. Zhai Y, Yu J, Iruela-Arispe L, Huang WQ, Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, Ni J, Yu GL and Li LY: Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82: 131-136, 1999.
8. Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S, Rojas L, Aggarwal BB, Ruben S, Li LY, Gentz R and Yu GL: VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13: 181-189 1999.
9. Jin T, Guo F, Kim S, Howard A and Zhang YZ: X-ray crystal structure of TNF ligand family member TL1A at 2.1A. Biochem Biophys Res Commun 364: 1-6, 2007.
10. Jin T, Kim S, Guo F, Howard A and Zhang YZ: Purification and crystallization of recombinant human TNF-like ligand TL1A. Cytokine 40: 115-122, 2007.
11. Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S and Li LY: A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 16: 742-744, 2002.
12. Yue TL, Ni J, Romanic AM, Gu JL, Keller P, Wang C, Kumar S, Yu GL, Hart TK, Wang X, Xia Z, DeWolf WE Jr and Feuerstein GZ: TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. J Biol Chem 274: 1479-1486, 1999.
13. Hou W, Medynski D, Wu S, Lin X and Li LY: VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res 11: 5595-5602, 2005.
14. Parr C, Gan CH, Watkins G and Jiang WG: Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9: 73-81, 2006.
15. Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS and Targan SR: The T-cell co-stimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol 178: 4033-4038, 2007.
16. Jiang WG, Hiscox S, Hallett MB, Scott C, Horrobin DF and Puntis MC: Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid. Br J Cancer 71: 744-752 1995.
17. 2+. Exp Cell Res 220: 424-433, 1995.
18. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mokbel K and Mansel RE: Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 11: 6012-6019, 2005.
19. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD and Mansel RE: Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med 17: 583-590, 2006.
20. Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L and Mansel RE: Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer 7: 71-80, 2008.
21. Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL and Li LY: Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res 89: 1161-1167, 2001.
22. Haridas V, Shrivastava A, Su J, Yu GL, Ni J, Liu D, Chen SF, Ni Y, Ruben SM, Gentz R and Aggarwal BB: VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene 18: 6496-6504, 1999.
23. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395, 2000.
24. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC and Vogelstein B: Clonal origin bladder cancer. N Engl J Med 326: 737-740, 1992.
25. Vriesema JL, Aben KK, Witjes JA, Kiemeney LA and Schalken JA: Superficial and metachronous invasive bladder carcinomas are clonally related. Int J Cancer 93: 699-702, 2001.
26. Goto K, Konomoto T, Hayashi K, Kinukawa N, Naito S, Kumazawa J and Tsuneyoshi M: p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas. Mod Pathol 10: 428-437, 1997.
27. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM and Wei P: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T-cell co-stimulator. Immunity 16(3): 479-492, 2002.
28. Cassatella MA, Pereira-da-Silva G, Tinazzi I, Facchetti F, Scapini P, Calzetti F, Tamassia N, Wei P, Nardelli B, Roschke V, Vecchi A, Mantovani A, Bambara LM, Edwards SW and Carletto A: Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol 178: 7325-7333, 2007.
29. Bamias G, Martin C 3rd, Marini M, Hoang S, Mishina M, Ross WG, Sachedina MA, Friel CM, Mize J, Bickston SJ, Pizarro TT, Wei P and Cominelli F: Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 171: 4868-4874, 2003.
30. Bamias G, Mishina M, Nyce M, Ross WG, Kollias G, Rivera-Nieves J, Pizarro TT and Cominelli F: Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci USA 103(22): 8441-8446, 2006.